Found 152 articles
8/2/2021With the Alzheimer’s Association International Conference conference last week, there were plenty of clinical trial news and updates. Here’s a look.
Annovis Bio’s therapy for Alzheimer’s disease is fast-acting and has the potential for Alzheimer’s patients to significantly improve cognition and motor function, according to data presented at the Alzheimer’s Association International Conference® 2021 (AAIC®), held July 26th through 30th.
Annovis Bio Pleased by Positive Interim Results from Ongoing Phase II Clinical Trials of ANVS401 (Posiphen) for the Treatment of Alzheimer's Disease and Parkinson's Disease
ANVS401's Interim Clinical Data Demonstrate Statistically Significant Improvements in Cognitive Function in AD Patients and Motor Function in PD Patients.
Annovis Bio Presents New Clinical and Biomarker Data at 2021 Alzheimer's Association International Conference.
The second part of the panel discussion will feature the clinical study and clinical data of the first 28 patients treated with ANVS401 in the Company's ongoing Phase 2a trials.
New efficacy and biomarker data to be featured in panel presentation on Wednesday, July 28.
Safety and tolerability data for Cohort 2 of the Discover Study reviewed by Data Safety Monitoring Board, allowing the study to proceed with the final cohort
Annovis Bio to Present Data at Alzheimer's Association International Conference 2021 Highlighting Positive Clinical Outcomes from Its Two Phase 2a Trials
Annovis Bio, Inc. (NYSE American: ANVS), ("Annovis" or the "Company"), a clinical-stage drug platform company addressing Alzheimer's disease (AD), Parkinson's disease (PD) and other neurodegenerative diseases, with data from two phase 2 studies showing its lead compound improves cognition in AD patients and motor function in PD patients...
The awards, hosted annually by the Philadelphia Alliance for Capital and Technologies (PACT), celebrate innovation in science and technology in the Philadelphia region.
The awards ceremony will take place from 4:30 p.m. to 5:30 p.m. ET on June 30 and can be viewed online: https://www.youtube.com/watch?v=KSzTe3dY0RY.
It’s been a bumpy ride for Biogen as news swirls around its overall Alzheimer’s program… but not for its competitors with investigational therapies for that disease.
A corporate presentation by Maria L. Maccecchini, Ph.D., CEO of Annovis Bio, will be available to registered attendees beginning at 9:00 a.m. ET on June 10.
Annovis Bio Expands Potential Application of ANVS401 to Infectious Diseases with New Preclinical Study
Preliminary data shows ANVS401 protects some types of nerve cells from dying after being infected by gingipains, the virulence factors of P. gingivalis
The presentation will be webcast live and archived for 30 days thereafter.
AD and PD patients both respond with a statistically significant increase in correctly coded fields after 25 days of treatment with ANVS401.
Annovis Bio Engages Global Executive Search Leader Spencer Stuart to Expand its Board and Management Team
After a thorough and extensive review of many impressive firms, we are excited to announce the selection of Spencer Stuart as our leadership advisor,
All of the shares of common stock are being offered by the Company.
INmune Bio, Inc. to Participate in Alzheimer Disease Panel Presented by Maxim Group LLC and hosted by M-Vest on May 26th, 2021
INmune Bio, Inc. (NASDAQ: INMB) (the, “Company”), a clinical-stage immunology company focused on developing treatments that harness the patient’s innate immune system to fight disease, announced today that RJ Tesi, MD, chief executive officer, has been invited to present at Alzheimer Disease Panel , presented by Maxim Group LLC and hosted by M-Vest, on Wednesday May 26th, 2021.
The offering is expected to close on May 26, 2021, subject to satisfaction of customary closing conditions.
Preliminary data from Annovis Bio’s Phase II study of ANVS401 shows significant cognitive improvements in Alzheimer’s patients after only one month of treatment.
ThinkEquity, a division of Fordham Financial Management, Inc., is acting as the sole book-running manager for the offering and Maxim Group LLC is acting as co-manager for the offering.